RE:RE:RE:An Interview With Baxter On Sepsis Nevertheless this confirms that Baxter has a keen interest in solving the Sepsis dilemma. Which is also demonstrated by the fact that they own Oxiris, a hemopurfusion filter that removes inflammatory mediators. However this product has had only mixed success in the past and currently has no FDA trial underway.
Surely they would be keenly interested in a FDA approved filter that is proven to do the job and that would represent the first improvement in treating Sepsis in decades ( a leading cause of AKI) and something that would introduce high margins versus the plethora of other much lower margin products and equipment that they provide to the majority of hospitals across the US.
The real money is in FDA approved drugs and devices that save lives and where there are patents and exclusivity.
MM